Skip to main content

Cabozantinib tablets online | Blueberry Pharmaceuticals

CABOZANTINIB

It belongs to the targeted therapy drug used to cure medullary thyroid cancer and kidney cancer that has spread. Cabozantinib label includes a black box warning of gastrointestinal perforations, fistulas, and haemorrhage. Cabozantinib is a prescription drug which is used under the supervision of doctors

INDICATION

Cabozantinib is indicated for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy.

MECHANISM OF ACTION

Cabozantinib belongs to a type of targeted therapy drug known as a tyrosine kinase inhibitor. It acts by inhibiting the signals inner cancer cells which made them grow and divide. This may help to block or reduced the growth of cancer. It can also prohibit new blood vessels growing in cancer. Cancer cells require to make new blood vessels so they can develop and spread.

DOSAGE AND ADMINISTRATION

The prescribed dose of Cabozantinib is 60 mg.
Administration Cabozantinib is without food.
Advise the patients not to eat for at least 2 hours before and 1 hour after taking Cabozantinib. Follow the treatment until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Swallow Cabozantinib tablets whole. Do not crush Cabozantinib tablets.

SIDE EFFECTS

• Haemorrhage
• GI perforations and fistulas
• Thrombotic events
• Hypertension and hypertensive crisis
• Diarrhea
• Palmar-plantar erythrodysesthesia
• Reversible posterior leukoencephalopathy syndrome

PRECAUTIONS

Check the patients for symptoms of perforations and fistulas, contain abscess. stop Cabozantinib in patients who experience a perforation or a fistula. Avoid administer Cabozantinib to patients with a present history of haemorrhage or haemoptysis. Stop the Cabozantinib in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.

DRUG-DRUG INTERACTION

While interaction with a strong CYP3A4 inhibitor will increase the single dose plasma Cabozantinib exposure by 38%. While interaction with strong CYP3A4 inducers will decrease the single dose plasma Cabozantinib exposure by 77%. The combination with MRP2 inhibitors may increase the exposure to Cabozantinib

CONTRAINDICATIONS

Cabozantinib has contraindicated patients having a hypersensitivity reaction to the active substance or its excipients.

STORAGE

Store the drug at below 25°C Keep away from the children resistances

MISSED DOSE

If the patient vomits after taking a dose of Cabozantinib or missed to take a dose, they should not take an extra dose, but to take the next dose at the regular time, skip the missed dose. Do not take the missed dose within 12 hours of the next dose.

FOR MORE INFORMATION:


EMAIL:
info@blueberrypharma.com

PHONE:
+91-97890 77748

VISIT US:
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Everotas 5 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Everotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide. USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib. Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with
Post a Comment
Read more

Rapact 10 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Rapact 10mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Rapact 10mg is an immunosuppressive macrolide. USED FOR Breast cancer  Patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. Rapact 10mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Rapact 10mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Rapact 10mg after the failure of treatment with Sunitinib or Sorafenib. Rapact 10mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Rapact is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Rapact bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex
Post a Comment
Read more